GM Advisory Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
Other funds holding RETA
CI
GM Advisory Group's RETA Position: Q4 2021 in Review
GM Advisory Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2021, closing a stake of 2,464 shares — an estimated $248K sold.
GM Advisory Group first reported a position in RETA in Q1 2020 and held it in 6 quarters. The position peaked at $475K in Q2 2020. 151 funds tracked by Wall St. Rank hold RETA as of Q4 2021.
- GM Advisory Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2021 after selling out during the quarter.
- GM Advisory Group sold 2,464 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2021, an estimated $248K.
- GM Advisory Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2020 and held it in 6 quarters.
- GM Advisory Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $475K in Q2 2020.
- 151 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2021.
Based on GM Advisory Group's 13F filing for Q4 2021, filed 10 Feb 2022.